SNDX Michael A Metzger sells $2.6M worth of shares
Sep 09, 2025, 4:36 AM
0.00%
What does SNDX do
Syndax Pharmaceuticals, based in Waltham, Massachusetts, develops cancer therapies and went public on March 3, 2016. Key products include revumenib for leukemia and axatilimab for chronic graft-versus-host disease.
Michael A Metzger sold 157,307 shares of SNDX on 8 September at $16.41 per share, worth a total of $2.6M. They now own 298,661 SNDX shares, or a 34% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.